Authors: M. Wawruch 1; L. Božeková 1; L. Magulová 2; D. Dostálová 3; J. Sládeková 1; M. Kriška 1 Authors‘ workplace: Farmakologický ústav, Lekárska fakulta Univerzity Komenského, Bratislava prednosta prof. MUDr. Milan Kriška, DrSc. 2Oddelenie klinickej farmakológie, Fakultná nemocnica s poliklinikou, Nitra primár MUDr. Jana Sirotiaková, PhD. 3Kožná klinika, Fakultná nem 1 Published in: Čes-slov Derm, , 2004, No. 1, p. 8-13 Category:
Antimycotics are the most frequently applied group of remedies in dermatology. They are appliedlocally as well as systemically. Their systemic application is connected with the risk of mutualinteractions with other simultaneously applied drugs. Such risk is greater namely in patients withseveral diseases, who take many remedies. In such patients the weakened immune function predisposesthem to mycotic infection. Antimycotics have a marked interactive potential because they areable to inhibit cytochrome P450 isoenzymes which largely participate in the metabolism of otherxenobiotics. The slowing down of biotransformation can lead to cumulation of drugs in the organismand to the manifestation of adverse effects. On the other hand, the pharmacokinetics of antimycoticscan be influenced by other drugs, namely by substances capable of accelerating their metabolismbythe induction of biotransformation enzymes. The basic prerequisite for preventing interactions isa high level of the physician’s knowledge about combinations under risk. Presented is a review ofclinically important interactions of azole antimycotics and terbinafin.
Key words: azole antimycotics - terbinafin - interaction - enzyme inhibition - enzyme induction
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
